Drug profile · INN
lenacapavir sodium
SUNLENCA
lenacapavir sodium (SUNLENCA) is a structural capsid protein inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — lenacapavir sodium
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
lenacapavir sodium (SUNLENCA) is a structural capsid protein inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Structural capsid protein inhibitor
Primary target: Structural capsid protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lenacapavir sodium?
lenacapavir sodium (SUNLENCA) is a structural capsid protein inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for lenacapavir sodium?
SUNLENCA is a marketed brand name for lenacapavir sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lenacapavir sodium?
lenacapavir sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.